Inhibikase Therapeutics (IKT)
Develops IKT-001 as a clinical-stage therapy for pulmonary arterial hypertension.
Something off on this page? Send us feedback.
Develops kinase-inhibitor therapeutics, with current work centered on IKT-001 for pulmonary arterial hypertension. The business has no approved drugs or product-sales revenue, runs as one reportable segment, and depends on clinical execution, regulatory approval, tolerability, financing, and competition in PAH.
Develops protein kinase inhibitor therapeutics rather than marketed drugs. Current work centers on IKT-001, an oral prodrug of imatinib mesylate for pulmonary arterial hypertension, with IMPROVE-PAH enrolling globally after the company redirected resources toward PAH.
The business is pre-commercial, has no approved products or product-sales revenue, and reports one operating segment. Operations are run from Wilmington, Delaware, with a small full-time employee base and leadership reset under Mark Iwicki after the founder-CEO transition.
Execution depends on enrolling and completing IMPROVE-PAH, securing regulatory approval, showing a tolerability profile that can matter versus imatinib, maintaining financing, and competing with approved and investigational PAH therapies.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 31, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $5 | Target: $8 |
| Jun 10, 2026 | Oppenheimer | Target | Target: — | Target: $5 |
| Dec 11, 2025 | Cantor Fitzgerald | Target | Target: — | Target: $4 |
| Feb 12, 2025 | HC Wainwright & Co. | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $159.0M · Total debt $0 · Total assets $163.6M · Shareholders' equity $153.3M
- Revenue
- $0
- Operating income
- −$21.1M
- Net income
- −$19.6M
No dividends on record.
| Institutions | ≈ 84.66% | 118.13M shares | |
|---|---|---|---|
| 107 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.31% | 3.23M shares | |
| 7 holders · as of Jul 31, 2026 | |||
| Strategic holders | 14.33% | 19.99M shares | |
| 2 holders · as of Jul 31, 2026 | |||
| Adds to | 101.30% | ||
139.54M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.30%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sands Capital Ventures, LLCInstitution | 9.33% | 13.02M | as of Jun 30, 2026 |
Sands Capital Life Sciences Pulse Fund II, L.P.1,2Strategic10 percent owner | 9.33% | 13.02M | filed Feb 13, 2026 |
Perceptive Life Sciences Master Fund, Ltd.Institution | 9.06% | 12.64M | filed May 15, 2026 |
Soleus Capital Management, L.P.Institution | 7.79% | 10.88M | as of Jun 30, 2026 |
Trails Edge Capital Partners, LPInstitution | 6.49% | 9.05M | as of Jun 30, 2026 |
- Sands Capital Life Sciences Pulse Fund II, L.P.'s transaction reports restate only vehicles that traded; the 2026 ownership statement (13.02M) is used instead.
- Sands Capital Life Sciences Pulse Fund II, L.P. reports a block also reported by Sands Capital Ventures, LLC; it is counted once, under Sands Capital Ventures, LLC.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | +2,068,965 | $1.45 |
- Merck
Approved PAH disease-remodeling rival with WINREVAIR
- Johnson & Johnson
Established oral PAH franchise across key treatment pathways
- United Therapeutics
Treprostinil PAH leader with inhaled, oral, and infused products
- Liquidia
New inhaled treprostinil entrant with YUTREPIA launch
- Gossamer Bio
Investigational inhaled kinase-pathway PAH competitor
- Insmed
Once-daily inhaled prostanoid challenger advancing TPIP
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics | $2.29 | +4.00% | $290.5M | — | — | — | — |
| Merck | $151.53 | +1.36% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| Johnson & Johnson | $268.53 | −0.35% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| United Therapeutics | $493.65 | +0.11% | $20.93B | 17.7 | 19.1 | 6.6 | −1.9% |
| Liquidia | $67.40 | +1.46% | $5.91B | 48.5 | 15.1 | 13.1 | +1,842.7% |
| Gossamer Bio | $11.77 | +4.30% | $68.9M | — | — | 1.3 | −19.6% |
| Insmed | $120.04 | −0.80% | $26.23B | — | — | 23.1 | +296.1% |
| Median | 39.9 | 18.3 | 6.6 | +5.8% |